• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med. COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature

tetano

Editor, Senior Moderator
J Clin Med. 2020 May 11;9(5). pii: E1420. doi: 10.3390/jcm9051420.
COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.


Kukla M[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Skonieczna-Żydecka K[SUP]4[/SUP], Kotfis K[SUP]5[/SUP], Maciejewska D[SUP]4[/SUP], Łoniewski I[SUP]4[/SUP], Lara LF[SUP]6[/SUP], Pazgan-Simon M[SUP]3,[/SUP][SUP]7[/SUP], Stachowska E[SUP]4[/SUP], Kaczmarczyk M[SUP]8[/SUP], Koulaouzidis A[SUP]9[/SUP], Marlicz W[SUP]10[/SUP].

Author information




Abstract

The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted.



KEYWORDS:

COVID-19; MERS; SARS; SARS-CoV-2; coronavirus; liver; pandemic


PMID:32403255DOI:10.3390/jcm9051420
 
Back
Top Bottom